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The concept that persistent feto-
placental intolerance is important in the 
pathogenesis of preeclampsia (PE) has 
been demonstrated by our lab and 
others. Arginine vasopressin (AVP) 
infusion during pregnancy induces 
cardiovascular, renal, and immune 
alterations in mice consistent with 
human PE. These findings identify AVP 
as a potential contributor to poor fetal 
tolerance and the development of PE. In 
addition to their conventional immuno-
stimulatory role, dendritic cells (DCs) 
also play a vital role in immune 
tolerance. In contrast to conventional 
DCs, regulatory DCs (DCregs) express 
low levels of co-stimulatory markers, 
produce anti-inflammatory cytokines, 
induce T regulatory cells, and promote 
tolerance. In mice, DCregs are able to 
prevent pro-inflammatory responses and 
induce antigen-specific tolerance. Given 
these known functions of DCregs, we 
hypothesize that DCregs will prevent the 
development of AVP-induced PE.  
C57BL/6J dams were infused with AVP 
(24 ng/hour) or saline throughout 
gestation via osmotic minipump. To 
generate DCregs, bone marrow derived 
cells from C57BL/6J mice were cultured 
with human TGF-b1, and murine GM-
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CSF and IL-10 and phenotype 
confirmed via flow cytometry. At the time 
of pump implantation or early post-
placentation on gestational day (GD) 7, 
AVP dams received a single intravenous 
injection of DCregs. Blood pressure was 
taken throughout pregnancy and total 
urine protein was measured on GD 17. 
Maternal tissues were collected on GD 
18. Cytokine concentrations were 
determined via commercially available 
ELISAs and normalized to total protein.  
Treatment of AVP-infused dams with 
DCregs before mating (GD -3) and on 
GD 7 prevented AVP-induced 
hypertension (AVP: 120 ±1.8, n=27 vs 
GD -3: 108 ±3.3, n=7 vs GD 7: 110 ±4.4, 
n=5 p<0.05) and elevations in urine 
protein (AVP: 37.4 ±2.3, n=24 vs GD -3: 
25.6 ±2.9, n=7 vs GD 7: 24.1 ±3.1, n=5 
p<0.05). Treatment with DCregs also 
reversed AVP-induced suppression of 
anti-inflammatory TGFb (AVP: 1.3, n=9 
vs GD -3: 3.2, n=7 vs GD 7: 2.9, n=5 
ug/g, p<0.05) in the plasma.  
These data support the hypothesis that 
DCreg treatment prevents AVP-induced 
PE. It further provides evidence for the 
use of personalized, cellular therapy in 
the prevention of cardiovascular, renal, 
and immune alterations induced in PE.  
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